Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;35(11):e21945.
doi: 10.1096/fj.202002526RR.

Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs

Licy L Yanes Cardozo  1   2   3   4   5 , Damian G Romero  1   3   4   5
Affiliations

Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs

Licy L Yanes Cardozo et al. FASEB J. 2021 Nov.

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder and the most common cause of androgen excess in reproductive-age women. The heterogeneity of the clinical presentation in PCOS patients suggests the involvement of multiples abnormal physiological pathways. In addition, women with PCOS have a high prevalence of cardiometabolic risk factors. Unfortunately, limited effective evidence-based therapeutic agents are available to treat the cardiometabolic complications in PCOS patients. Insights from recent studies highlight the multiple opportunities to deliver timely effective medical care for women with PCOS. This perspective manuscript aims to highlight the unmet need for effective and safe management of the cardiometabolic complications in PCOS patients.

Keywords: androgen receptor; androgens; cardiovascular diseases; cardiovascular risk factors; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Similar articles

See all similar articles

Cited by

References

    1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, and Yildiz BO (2016) The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod 31, 2841–2855 - PubMed
    1. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, and Boots LR (2004) Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab 89, 453–462 - PubMed
    1. Rotterdam, E. A.-S. P. c. w. g. (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod 19, 41–47 - PubMed
    1. Zawadski JK, and Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome (Dunaif A, Givens JR, Haseltine FP, and Merrian GR, eds) pp. 377–384, Blackwell Scientific Publications, Boston
    1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, and Androgen Excess S (2006) Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab 91, 4237–4245 - PubMed

Publication types

MeSH terms